Harrow Inc. Common Stock (HROW)

FairStock Score: 35/100 — MIXED

Key Financials

Strengths

• Strong Piotroski F-Score of 7/9 indicating robust financial health across profitability, leverage, and efficiency metrics
• Revenue growth of 33.3% demonstrates strong top-line momentum

Concerns

• High leverage at 10.61x debt-to-equity increases financial risk and interest expense burden

AI Analysis

Harrow Inc. Common Stock is a micro-cap healthcare company valued at $1.4 billion. The business generates $269 million in annual revenue with a 2.5% net margin. From a quality standpoint, Harrow shows solid Piotroski F-Score of 7/9 and Altman Z-Score of 2.6 in the grey zone. On valuation, the stock is 0.6% FCF yield. Growth dynamics show revenue growing at 33.3% and profit growth of -2.2%. Our composite FairStock Score of 35/100 reflects below-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Harrow's 33% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.

Bear Case

Elevated leverage at 10.6x D/E means rising interest rates or revenue weakness could strain debt covenants and force asset sales at distressed prices. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer